Relación entre ácidos grasos omega-3/omega-6 presentes en la dieta y enfermedad inflamatoria intestinal: Scoping review
DOI:
https://doi.org/10.14306/renhyd.23.2.720Palabras clave:
Enfermedades Inflamatorias del Intestino, Ácidos Grasos Omega-3, Ácidos Grasos Omega-6, Dietoterapia, Dieta.Resumen
Introducción: La enfermedad inflamatoria intestinal (EII) incluye a la colitis ulcerosa (CU) y la enfermedad de Crohn (EC). Se cree que las grasas dietéticas pueden influir en su desarrollo. Objetivo: Analizar cómo se relaciona el contenido de omega-3 y omega-6 presentes en la dieta de forma natural con el proceso de la EII, tanto en su aparición como en su periodo de remisión.
Material y métodos: Fuentes de datos: Se realizaron la búsqueda en las bases de datos Scopus y PubMed. Criterios de elegibilidad: Se incluyeron los estudios publicados entre 2007 y 2017, en español e inglés, diseño cuantitativo y cualitativo sobre el tema de estudio. Se excluyeron los estudios sobre fármacos o suplementos, animales y dieta en otras patologías. Evaluación de los estudios: Los estudios fueron evaluados a través de la Guía CASPe y los objetivos propios del diseño de scoping review.
Resultados: Un total de 14 artículos fueron incluidos.
Conclusiones: Hay evidencia de que el consumo de omega-3 y omega-6 puede influir en el desarrollo de la EII. Aunque no existen recomendaciones dietéticas definidas para las personas con EII, sería fundamental crear una guía de alimentación para el control de esta patología.
Citas
(1) Shi Y, Zhou J, Jiang B, Miao M. Resveratrol and inflammatory bowel disease. Ann N Y Acad Sci. 2017; 1403(1):38-47. doi: 10.1111/nyas.13426.
(2) Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein Ch, Brandt SR et al. Toward and integrated clinical, molecular, and serological classification of inflammatory bowel disease: report or a working party of the Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(A):5-36.
(3) Sainsbury A, Heatley RV. Review article: Psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21(5):499-508.
(4) Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46-54. e42.
(5) Bosques-Padilla FJ, Sandoval-Garcia ER, Martinez-Vazquez MA, Garza-Gonzalez E, Maldonado-Garza HJ. Epidemiology and clinical characteristics of ulcerative colitis in north-eastern Mexico. Rev Gastroenterol Mex 2011 Jan-Mar;76(1):34-8.
(6) Marteau P, Allez M, Jian R. Enfermedad de Crohn. EMC - Tratado de Medicina 2013 12;17(4):1-8.
(7) Gassull MA, Gomollón F, Obrador A, Hinojosa J, eds. Enfermedad Inflamatoria intestinal. 2ª ed. Madrid: Ergon; 2002.
(8) Tasson L, Canova C, Vettorato MG, Savarino E, Zanotti R. Influence of Diet on the Corse of Inflammtory Bowel Disease. Dig Dis Sci. 2017;62(8):2087-94. doi: 10.1007/s10620-017-4620-0.
(9) Shivashankar R, Lewis JD. The Role of Diet in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2017;19(5):22. doi: 10.1007/s11894-017-0563-z.
(10) Rapozo DC, Bernardazzi C, de Souza HS. Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World J Gastroenterol. 2017 Mar 28;23(12):2124-2140. doi: 10.3748/wjg.v23.i12.2124.
(11) Guarner F. Microbiota intestinal y enfermedades inflamatorias del intestino. Gastroenterol Hepatol 2011;34:147-54.
(12) Yamamoto T, Shimoyama T, Kuriyama M. Dietary and enteral inteerventions for Crohn’s disease. Curr Opin Biotechnol. 2017;44:69-73. Doi: 10.1016/j.copbio.2016.11.011.
(13) Triantafyllidis I, Poutaahidis T, Taitzoglou I, KEsisoglou I, Lazaridis C, Botsios D. Treatment with Mesna and n-3 polyunsaturated fatty acids ameliorates experimental ulcerative colitis in rats. Int J Exp Pathol. 2015;96(6):433-43. doi: 10.1111/iep.12163
(14) Cabré E, Mañosa M, Gassul MA. Omega-3 fatty acids and inflammatory bowel diseases – a systematic review. Br J Nutr 2012;107:S240-52. Doi:10.1017/S0007114512001626
(15) Armstrong R, Hall BJ, Doyle J, Waters E. “scoping the scope” of a cochrane review. J Public Health 2011;33:147-50.
(16) Cabello, J.B. por CASpe. Plantilla para ayudarte a entender un Ensayo Clínico. En: CASPe de Lectura Crítica de la Literatura Médica. Alicante: CASPe; 2005. Cuaderno l. p.5-8.
(17) Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(1):g7647.
(18) Skrautvol K, Nåden D. Nutrition as long-term care as experienced by persons living with inflammatory bowel disease: a qualitative study. Holist Nurs Pract 2015;29(1):22-32.
(19) Uchiyama K, Nakamura M, Odahara S, Koido S, Katahira K, Shiraishi H, et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16(10):1696-707.
(20) Ananthakrishnan AN, Khalili H, Song M, HigCUhi LM, Richter JM, Nimptsch K, et al. High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases 2015;21(10):2311-9.
(21) Chan SSM, Luben R, Olsen A, Tjonneland A, Kaaks R, Lindgren S, et al. Association between high dietary intake of the n−3 polyunsaturated fatty acid docosahexaenoic acid and redCUed risk of Crohn's disease. Alimentary Pharmacology & Therapeutics 2014;39(8):834-42.
(22) Marlow G, Ellett S, Ferguson IR, Zhu S, Karunasinghe N, Jesuthasan AC, et al. Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients. Human genomics 2013;7(1):24.
(23) Hart AR, Luben R, Olsen A, Tjonneland A, Linseisen J, Nagel G, et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion 2008;77(1):57-64.
(24) Pugazhendhi S, Sahu MK, Subramanian V, Pulimood A, Ramakrishna BS. Environmental factors associated with Crohn's disease in India. Indian J Gastroenterol 2011;30(6):264-9.
(25) Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol 2007;102(9):2016-25.
(26) Ferreira P, Cravo M, Guerreiro CS, Tavares L, Santos PM, Brito M. Fat intake interacts with polymorphisms of Caspase9, FasLigand and PPARgamma apoptotic genes in modulating Crohn's disease activity. Clin Nutr 2010;29(6):819-23.
(27) Rashvand S, Somi MH, Rashidkhani B, Hekmatdoost A. Dietary fatty acid intakes are related to the risk of ulcerative colitis: a case–control study. Int J Colorectal Dis 2015;30:1255-60. DOI: 10.1007/s00384-015-2232-8
(28) Tjonneland A, Overvad K, Bergmann MM, Nagel G, Linseisen J, Hallmans G, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009 Dec;58(12):1606-11.
(29) Pearl DS, Masoodi M, Eiden M, Brümmer J, Gullick D, McKeever TM, et al. Altered colonic mCUosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. J Crohns Colitis 2014;8(1):70-9.
(30) Shivappa N, Hébert JR, Rashvand S, Rashidkhani B, Hekmatdoost A. Inflammatory Potential of Diet and Risk of Ulcerative Colitis in a Case-Control Study from Iran. Nutr Cancer 2016;68(3):404-9.
(31) Grimstad T, Berge RK, Bohov P, Skorve J, Gøransson L, Omdal R, et al. Salmon diet in patients with active ulcerative colitis redCUed the simple clinical colitis activity index and increased the anti-inflammatory fatty acid index--a pilot study. Scand J Clin Lab Invest 2011;71(1):68-73.
(32) Galli C, Calder PC. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann Nutr Metab 2009;55(1-3):123-39.
(33) Umoh F, Kato I, Ren J, Wachowiak P, Ruffin IV M, Turgeon D, et al. Markers of systemic exposures to products of intestinal bacteria in a dietary intervention study. Eur J Nutr 2016 Mar;55(2):793-8.
(34) Kakodkar S, Farooqui AJ, Mikolaitis SL, Mutlu EA. The Specific Carbohydrate Diet for Inflammatory Bowel Disease: A Case Series. Journal of the Academy of Nutrition and Dietetics 2015;115(8):1226-32.
(35) Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011 Apr;106(4):563-73. doi: 10.1038/ajg.2011.44.
(36) Devkota S, Chang EB. Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases. Digestive diseases (Basel, Switzerland) 2015;33(3):351-6.
(37) García-Sanjuán S, Lillo-Crespo M, Sanjuán-Quiles Á, Richart-Martínez M. Dietary habits and feeding beliefs of people with Crohn's disease. Nutr Hosp 2015;32(6):2948-55.
(38) Lewis JD, Abreu MT. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. Gastroenterology 2017;152(2):398-414.
(39) Mozaffari H, Daneshzad E, Larijani B, Bellissimo N, Azadbakht L. Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2019 Jan 24. pii: 10.1007/s00394-019-01901-0. doi: 10.1007/s00394-019-01901-0.
(40) Andersen V, Olsen A, Carbonnel F, Tjønneland A, Vogel U. Diet and risk of inflammatory bowel disease. Dig Liver Dis 2012;44(3):185-94.
(41) Wang L, Lim EJ, Toborek M, Hennig B. The role of fatty acids and caveolin-1 in tumor necrosis factor alpha-induced endothelial cell activation. Metabolism 2008;57:1328-39.
(42) Kyaw MH, Moshkovska T, Mayberry J. A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life. Eur J Gastroenterol Hepatol 2014;26(8):910-917.
(43) Simopoulos AP. Omega-3 fatty acids in inflammation and autoinmune diseases. J Am Coll Nutr 2002; 21:495–505.
(44) ECCO-EFCA CD Patient Guidelines in Spain. Available at: https://www.ecco-ibd.eu/publications/ecco-efcca-patient-guidelines/cd-patient-guidelines/file/cd-patient-guidelines/cd-patient-guidelines-in-spanish.html Accessed Feb 20, 2018.
(45) ECCO-EFCA UC Patient Guidelines in Spain. Available at: https://www.ecco-ibd.eu/publications/ecco-efcca-patient-guidelines/uc-patient-guidelines/file/uc-patient-guidelines/uc-patient-guidelines-in-spanish.html Accessed Feb 20, 2018.
(46) García-Sanjuán S, Lillo-Crespo M, Richart-Martínez M, Sanjuán-Quiles A. Understanding life experiences of people affected by Crohn's disease in Spain. A phenomenological approach. Scand J Caring Sci. 2017 [Epub ahead of print] Doi: 10.1111/scs.12469
(47) Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J en representación del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Guía clínica GETECCU del tratamiento de la colitis ulcerosa elaborada con la metodología GRADE. Gastroenterol Hepatol. 2012. http://dx.doi.org/10.1016/j.gastrohep.2012.11.001
(48) García-Sanjuán S, Lillo-Crespo M, Sanjuán-Quiles Á, Richart-Martínez M. Enfermedad de Crohn: experiencias de vivir con una cronicidad. Salud Publica Mex 2016;58(1):49-55.
Esta revista ha conseguido la validación para ser 